Clinical significance of soluble adhesion molecules in anti‐<scp>NMDAR</scp> encephalitis patients

Ding, Yuewen; Yang, Cheng-Jia; Zhou, Zheyi; Yu, Peng; Chen, Jinyu; Pan, Suyue; Xu, Hong; Cai, Yuping; Ou, Kaiyun; Xie, Wei

doi:10.1002/acn3.740

Cited by 4 publications

(7 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our previous study showed the levels of sICAM-1, sVCAM-1 and sL-selectin in CSF were significantly elevated in anti-NMDAR encephalitis patients. Combined with our findings ( 30 ), it may share a similar pathophysiological mechanism in anti-NMDAR encephalitis. We hope to further explore this in our future research.…”

Section: Discussionsupporting

confidence: 88%

“…In previous studies, abnormal elevation of sCD146 has been reported to correlate with proinflammatory factors, such as TNF-α, IL-13 and IL-17 ( 5 , 27 ). Early research by our team confirmed that the presence of inflammatory factors in the CSF of anti-NMDAR encephalitis patients reflect the activity of the disease ( 8 , 9 , 17 , 28 – 30 ). In the present study, we considered that local inflammation in the brain was activated, leading to the accumulation of inflammatory factors in the CSF that enhanced the expression of sCD146, ultimately promoting BBB dysfunction.…”

Section: Discussionmentioning

confidence: 81%

See 1 more Smart Citation

High Level of Soluble CD146 In Cerebrospinal Fluid Might be a Biomarker of Severity of Anti-N-Methyl-D-Aspartate Receptor Encephalitis

Chen

Yin

et al. 2021

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

BackgroundDisruption of the blood–brain barrier (BBB) is an important pathophysiological process of anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis. A recent multi-center study showed that soluble (s) CD146 is a potential biomarker for monitoring early BBB damage and central nervous system inflammation, but little is known about sCD146 in anti-NMDAR encephalitis.MethodTwenty-three anti-NMDAR encephalitis patients and seventeen controls with non-inflammatory neurological diseases were recruited. sCD146 and inflammatory cytokines in cerebrospinal fluid (CSF) and serum were detected by ELISA. Modified Rankin scale (mRS) scores were used to assess the neurological status of each patient. A follow-up review was completed three months after discharge.ResultssCD146 levels in the CSF of patients with the acute stage anti-NMDAR encephalitis were significantly increased compared with controls and accompanied by increases in TNF-α, IL-6 and IL-10. CSF sCD146 was positively correlated with neuroinflammatory factors in the CSF and with mRS score. Three months after effective treatment, CSF sCD146 in patients was significantly decreased but remained significantly different compared with the controls.ConclusionOur data suggested that higher expression of CSF sCD146 correlated with more serious neurological damage. Therefore, levels of CSF sCD146 may represent a promising indicator for monitoring disease and optimizing clinical treatment decisions in the early stages of anti-NMDAR encephalitis.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 81%

High Level of Soluble CD146 In Cerebrospinal Fluid Might be a Biomarker of Severity of Anti-N-Methyl-D-Aspartate Receptor Encephalitis

Chen

Yin

et al. 2021

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, our research revealed that the poor prognosis of LGI1 encephalitis patients was associated with an increase in ICMA1 expression. ICAM1 is a transmembrane protein whose expression is elevated on endothelial and epithelial cells at sites of inflammation, is expressed on leukocytes and endothelial cells, and is upregulated in response to inflammatory signals [ 23 , 24 ]. ICAM1 has been linked to the pathophysiology of a number of autoimmune diseases and inflammatory syndromes, including gastric cancer, multiple sclerosis, and neuromyelitis optica [ 25 – 27 ].…”

Section: Discussionmentioning

confidence: 99%

“…ICAM-1-/- or mutant mice exhibited less T cell infiltration in the CNS and less clinical disability in a mouse model of multiple sclerosis [ 28 ]. In the anti-NMDAR encephalitis group, CSF levels of soluble ICAM1 were significantly higher in the patient cohort [ 23 ]. Notably, a significant positive association was observed between the severity of NMDAR encephalitis and the amount of ICAM1 in CSF [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

Abnormal DNA methylation analysis of leucine-rich glioma-inactivated 1 antibody encephalitis reveals novel methylation-driven genes related to prognostic and clinical features

Qiao,

Sun,

et al. 2023

Clin Epigenet

View full text Add to dashboard Cite

Background Aberrant DNA methylation occurs commonly during pathogenesis of neuroimmunological diseases and is of clinical value in various encephalitis subtypes. However, knowledge of the impact of DNA methylation changes on pathogenesis of leucine-rich glioma-inactivated 1 (LGI1) antibody encephalitis remains limited. Methods A total of 44 cytokines and 10 immune checkpoint moleculars (ICMs) in the serum of patients with LGI1 encephalitis and healthy donors (HDs) were measured to evaluate the association of them with clinical parameters. Genome-wide DNA methylation profiles were performed in peripheral blood mononuclear cell (PBMC) from LGI1 encephalitis patients and HDs using reduced representation bisulfite sequencing (RRBS) and validated for the methylation status by pyrosequencing. MicroRNA profiles were acquired in serum exosome by small RNA sequencing. Targeted cytokines expression was assessed at the presence or absence of miR-2467-5p in PBMCs and the culture media, and the binding of miR-2467-5p and its targeted genes was validated by luciferase assay. Results There existed significant difference in 22 cytokines/chemokines and 6 ICMs between LGI1 encephalitis patients and HDs. Decreased PDCD1 with increased ICAM1 could predict unfavorable prognosis in one-year follow-up for LGI1 encephalitis patients. Fifteen of cytokines/chemokines and ICMs presented DNA-methylated changes in the promoter and gene body using RRBS in which five were verified as methylation status by pyrosequencing, and the methylation level of CSF3, CCL2, and ICAM1 was conversely associated with their expression in PBMCs. By combining RRBS data with exosome-derived microRNA sequencing, we found that hypomethylated-driven hsa-miR-2467-5p presented elevated expression in serum exosomes and PBMCs in LGI1 encephalitis. Mechanically, miR-2467-5p significantly induced reduced expression of CSF3 and PDCD1 by binding with their 3`UTR while enhanced CCL15 expression, but not significantly correlated with peripheral blood CD19 + B cell proportion of LGI1 encephalitis patients. Conclusions Our results provided convincing evidence for DNA methylation changes, microRNA profiles in serum exosome for LGI1 encephalitis, and we also identified several novel cytokines related to clinical features in which some represented epigenetic modification of methylated-driven pattern and microRNA modulation. Our study contributed to develop treatment for epigenetic pathogenesis in LGI1 encephalitis.

show abstract

“…Yu et al observed BBB dysfunction based on the results of QAlb in anti-NMDAR encephalitis ( 154 ). Some chemical agents related to BBB damage and CNS inflammation are observed in the CSF and serum in anti-NMDAR encephalitis ( 155 , 156 ). Due to the impaired BBB, anti-NMDAR antibodies may transfer from pregnant C57BL/6J mice to fetuses, causing severe but reversible synaptic and neurodevelopmental alterations ( 157 ).…”

Section: Bbb Nmdars and Anti-nmdar Encephalitismentioning

confidence: 99%

Anti-NMDAR antibodies, the blood–brain barrier, and anti-NMDAR encephalitis

Gong,

Wang,

Zhu

et al. 2023

Front. Neurol.

View full text Add to dashboard Cite

Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is an antibody-related autoimmune encephalitis. It is characterized by the existence of antibodies against NMDAR, mainly against the GluN1 subunit, in cerebrospinal fluid (CSF). Recent research suggests that anti-NMDAR antibodies may reduce NMDAR levels in this disorder, compromising synaptic activity in the hippocampus. Although anti-NMDAR antibodies are used as diagnostic indicators, the origin of antibodies in the central nervous system (CNS) is unclear. The blood–brain barrier (BBB), which separates the brain from the peripheral circulatory system, is crucial for antibodies and immune cells to enter or exit the CNS. The findings of cytokines in this disorder support the involvement of the BBB. Here, we aim to review the function of NMDARs and the relationship between anti-NMDAR antibodies and anti-NMDAR encephalitis. We summarize the present knowledge of the composition of the BBB, especially by emphasizing the role of BBB components. Finally, we further provide a discussion on the impact of BBB dysfunction in anti-NMDAR encephalitis.

show abstract

Clinical significance of soluble adhesion molecules in anti‐NMDAR encephalitis patients

Cited by 4 publications

References 41 publications

High Level of Soluble CD146 In Cerebrospinal Fluid Might be a Biomarker of Severity of Anti-N-Methyl-D-Aspartate Receptor Encephalitis

High Level of Soluble CD146 In Cerebrospinal Fluid Might be a Biomarker of Severity of Anti-N-Methyl-D-Aspartate Receptor Encephalitis

Abnormal DNA methylation analysis of leucine-rich glioma-inactivated 1 antibody encephalitis reveals novel methylation-driven genes related to prognostic and clinical features

Anti-NMDAR antibodies, the blood–brain barrier, and anti-NMDAR encephalitis

Contact Info

Product

Resources

About